This study aimed to investigate the etiological profile of community-acquired pneumonia (CAP) in children and to provide evidence for the rational use of antimicrobial agents in clinical practice. A retrospective analysis was performed on 1,066 pediatric patients diagnosed with CAP between November 2024 and February 2025, examining clinical data including age, seasonal distribution, pathogen spectrum, and sputum culture findings. The results demonstrated distinct age and seasonal patterns in pathogen distribution: Mycoplasma pneumoniae was frequently detected across all age groups, with higher prevalence among school-aged children; respiratory syncytial virus was more common in infants and toddlers; and influenza virus infections peaked in winter and spring. Sputum cultures further revealed varying drug resistance profiles among bacterial isolates. In conclusion, the etiology of pediatric CAP is diverse and influenced by age and seasonal factors, underscoring the importance of etiology-guided antimicrobial therapy to optimize treatment outcomes.

Qinghe Song, Guangjian Han, Zhemin Li, Yang Guo, Ling Xin, Zhihua He. Analysis of Pathogen Distribution and Drug Resistance in 1,066 Cases of Community-Acquired Pneumonia in Children. International Journal of Frontiers in Medicine (2025), Vol. 7, Issue 4: 113-117. https://doi.org/10.25236/IJFM.2025.070414.

[1] Hongping Li, Hua Li. Investigation on Influencing Factors and Preventive Measures for Hospital-Acquired Pneumonia in Inpatients[J]. Maternal and Child Health Care of China, 2018, 33(15): 3511-3513.

[2] National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine. Diagnosis and Treatment Guidelines for Community-Acquired Pneumonia in Children (2019 Edition) [J]. Chinese Journal of Clinical Infectious Diseases, 2019, 12(1): 6-13.

[3] Xiaoyan Fu, Deli Xin, Xuanguang Qin. Research Progress in the Epidemiology, Clinical Characteristics, Pathogenesis, and Treatment of Mycoplasma pneumoniae Infection in Children[J]. Shandong Medical Journal, 2015, 55(4): 96-99.

[4] Loconsole D, De Robertis AL, Sallustio A, et al. Update on theepidemiology of macrolide-resistant mycoplasma pneumoniae in Europe: a systematic review[J]. Infect Dis Rep, 2021, 13(3):811-820. DOI: 10.3390/idr13030073.

[5] Waites KB, Ratliff A, Crabb DM, et al. Macrolide-resistant mycoplasma pneumoniae in the United States as determined from a national surveillance program[J]. J Clin Microbiol,2019, 57(11):16-19. DOI:10.1128/JCM.00968-19.

[6] Jiang TT, Sun L, Wang TY, et al. The clinical significance of macrolide resistance in pediatric mycoplasma pneumoniae infection during COVID-19 pandemic[J]. Front Cell Infect Microbiol,2023, 13:1181402. DOI:10.3389/fcimb.2023. 1181402.

[7] Jinni Chen. Analysis of pathogenic characteristics of 600 cases of community-acquired pneumonia in children [J]. Chinese Journal of Pathogenic Microbiology, 2016, 11 (12): 1126-1130.

[8] Chunmei Yu,Xiqiang Yang, Feng Xu, et al. Analysis of respiratory virus pathogens in infants and young children with severe pneumonia in Chongqing [J]. Chinese Journal of Pediatrics, 2010, 48 (2): 143-147.

[9] Jie Lin, Lin Dong, Haiyan Li, et al. Clinical characteristics and analysis of antibiotic use in severe respiratory syncytial virus pneumonia [J]. Journal of Clinical Pediatrics, 2011, 29 (5): 454-458.

[10] Mathew JL, Singhi S, Ray P, et al. Etiology of community acquired pneumonia among children in India: proapective, cohort study[J]. J Glob Health, 2015, 5(2): 50418.

[11] Jianmin Lin, Ling Chen, Qingrong Lian, et al. Analysis of the pathogenic characteristics of 5869 children with community-acquired pneumonia in the southern Fujian region [J]. Chinese Journal of Microbiology, 2018, 30 (10): 1160-1163.

[12] Jinqiang Deng, Investigation of pathogenic bacteria in community-acquired pneumonia in children and study on rational use strategies of antibiotics [J]. Modern Drug Application in China, 2018, 12 (7): 151-153.